于2026年9月30日,FMR LLC在联交所场内以每股均价14.5448港元卖出康臣药业(01681)8.30万股,涉资约120.72万港元,属场内主动交易,即在二级市场直接买卖股份。
FMR LLC此次减持前持有康臣药业好仓7581.76万股,占比9.01%;减持后持股量为7573.46万股,好仓比例降至8.99%。
于2026年9月30日,FMR LLC在联交所场内以每股均价14.5448港元卖出康臣药业(01681)8.30万股,涉资约120.72万港元,属场内主动交易,即在二级市场直接买卖股份。
FMR LLC此次减持前持有康臣药业好仓7581.76万股,占比9.01%;减持后持股量为7573.46万股,好仓比例降至8.99%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.